Norwegian national focal point
Since 2016 the Norwegian focal point has been located in the Norwegian Institute of Public Health (FHI). FHI acts as a national competence institution for governmental authorities, the health service, the judiciary, prosecuting authorities, politicians, the media and the general public on issues related to physical and mental health, prevention of communicable diseases and prevention of harmful environmental influences. It is placed directly under the Ministry of Health and Care Services.
News
Events
Publications
Publications related to this partner
The elimination barometer for hepatitis B and C among people who inject drugs is designed to support countries affiliated to the EMCDDA in monitoring their progress towards the Sustainable Development Goal 3.3 and the elimination of viral hepatitis as a major public health threat by 2030.
Heroin remains Europe’s most commonly used illicit opioid and is also the drug responsible for a large share of the health burden attributed to illicit drug consumption.
MDMA is a synthetic drug chemically related to the amphetamines, but with somewhat different effects. In Europe, MDMA use has generally been associated with episodic patterns of consumption in the context of nightlife and entertainment settings.
Amphetamine, methamphetamine and, more recently, synthetic cathinones are all synthetic central nervous system stimulants available on the drug market in Europe.
The market for new psychoactive substances is characterised by the large number of substances that have appeared in this area and that new compounds continue to be detected each year.
The European Drug Report 2023: Trends and Developments presents the EMCDDA’s latest analysis of the drug situation in Europe.
Document library
Media library
Related photos, infographics and videos from our Media library
Contact information
Norwegian Institute of Public Health
Ms Marit Edland-Gryt (Head of Focal Point)
Ms Ingeborg Lund (Vice-Head of National Focal Point)
Oslo
Norway